Published in Vaccine Weekly, October 11th, 2006
According to a report from the United States, "Docetaxel has demonstrated therapeutic efficacy against breast, prostate, and ovarian cancer and other solid tumors. The tumoricidal activity of docetaxel is mainly attributed to its ability to block microtubule depolymerization, thus inducing G(2)-M arrest and apoptosis."
"Mounting evidence indicates that docetaxel also possesses immunomodulatory activity such as augmenting...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly